Page last updated: 2024-09-03

y 27632 and Kidney Neoplasms

y 27632 has been researched along with Kidney Neoplasms in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Furukawa, S; Handa, H; Hashimoto, A; Hashimoto, S; Mikami, S; Oikawa, T; Okada, Y; Onodera, Y; Oya, M; Sabe, H; Sugino, H; Yoshikawa, A	1
Liao, AC; Nelson, LJ; Nesterenko, I; Nguyen, QH; Pavesic, MW; Razorenova, OV; Singh, M; Thompson, JM	1

Other Studies

2 other study(ies) available for y 27632 and Kidney Neoplasms

Article	Year
Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer. Nature communications, 2016, Feb-08, Volume: 7 Topics: ADP-Ribosylation Factor 6; ADP-Ribosylation Factors; Adult; Aged; Aged, 80 and over; Amides; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epithelial-Mesenchymal Transition; Female; GTP-Binding Protein alpha Subunits, G12-G13; Guanine Nucleotide Exchange Factors; HEK293 Cells; Humans; Immunohistochemistry; Indoles; Isoxazoles; Kidney Neoplasms; Lysophospholipids; Male; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Transplantation; Nerve Tissue Proteins; Propionates; Pyridines; Pyrroles; Receptors, Lysophosphatidic Acid; Signal Transduction; Sirolimus; Sunitinib; Triazoles	2016
Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma. Oncogene, 2017, 02-23, Volume: 36, Issue:8 Topics: Amides; Animals; Apoptosis; Biomarkers, Tumor; Carcinoma, Renal Cell; Cell Cycle; Cell Proliferation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Kidney Neoplasms; Mice; Pyridines; rho-Associated Kinases; RNA, Small Interfering; Tumor Cells, Cultured; Von Hippel-Lindau Tumor Suppressor Protein; Xenograft Model Antitumor Assays	2017

Article

Year

Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer.

Nature communications, 2016, Feb-08, Volume: 7

Topics: ADP-Ribosylation Factor 6; ADP-Ribosylation Factors; Adult; Aged; Aged, 80 and over; Amides; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epithelial-Mesenchymal Transition; Female; GTP-Binding Protein alpha Subunits, G12-G13; Guanine Nucleotide Exchange Factors; HEK293 Cells; Humans; Immunohistochemistry; Indoles; Isoxazoles; Kidney Neoplasms; Lysophospholipids; Male; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Transplantation; Nerve Tissue Proteins; Propionates; Pyridines; Pyrroles; Receptors, Lysophosphatidic Acid; Signal Transduction; Sirolimus; Sunitinib; Triazoles

2016

Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma.

Oncogene, 2017, 02-23, Volume: 36, Issue:8

Topics: Amides; Animals; Apoptosis; Biomarkers, Tumor; Carcinoma, Renal Cell; Cell Cycle; Cell Proliferation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Kidney Neoplasms; Mice; Pyridines; rho-Associated Kinases; RNA, Small Interfering; Tumor Cells, Cultured; Von Hippel-Lindau Tumor Suppressor Protein; Xenograft Model Antitumor Assays

2017